CTLA4 and neoplasm: Immune checkpoint inhibitors (ICIs), such as those targeting PD-1, PD-L1, or CTLA-4, have shown remarkable success in several cancer types by reactivating cytotoxic T cells to eliminate tumor cells14, 15.